Transfusion Testing - Type and Screen and Crossmatch

Key Points

• Patient identification at specimen collection is a core transfusion-safety step.
• A type and screen determines ABO/RhD and screens for clinically significant unexpected antibodies.
• A positive screen requires antibody identification and usually antigen-negative compatible red cells.
• Historical clinically significant antibodies remain relevant even when the current screen is negative.
• Electronic crossmatch is limited to patients who meet validated eligibility criteria.
• Recent transfusion or pregnancy shortens specimen validity because new alloantibodies can emerge.
• Emergency-release uncrossmatched blood is appropriate when hemorrhage is life threatening and compatibility testing would cause harmful delay.
• Transition from group O emergency blood to type-specific components as soon as safe testing permits.
• O RhD-negative red cells are a limited resource and should be reserved according to evidence-based policy.
• Complex antibody histories should be communicated early before elective surgery, delivery, or anticipated transfusion.

Algorithm

1. Confirm the clinical indication and urgency for transfusion.
2. Collect a correctly labeled sample using positive patient identification.
3. Perform ABO/RhD typing and antibody screen.
4. Confirm ABO through an approved historical or second-sample process when required.
5. If the antibody screen is negative and the patient is eligible, perform electronic or immediate-spin crossmatch according to policy.
6. If the screen is positive or there is a relevant antibody history, identify antibody and select antigen-negative units.
7. In life-threatening hemorrhage, issue emergency-release group O or otherwise policy-defined compatible blood without waiting for routine testing.
8. Switch to type-specific components promptly when reliable results are available.
9. Monitor for transfusion reactions and investigate any suspected event immediately.

Clinical Synopsis & Reasoning

A pretransfusion sample carries high patient-safety stakes because wrong-blood-in-tube errors can cause fatal ABO-incompatible transfusion. Positive patient identification at collection is therefore as important as the laboratory method. The transfusion service determines ABO and RhD type and performs an antibody screen against reagent red cells selected to detect clinically significant alloantibodies. Many institutions require confirmation of ABO type from a separate historical result or independently collected sample before electronically issuing type-specific units to a patient without a verified history.

The antibody screen is not a test for every red-cell antibody. It is optimized for clinically significant unexpected antibodies, particularly those reactive at body temperature and associated with hemolytic transfusion reactions or hemolytic disease of the fetus/newborn. If the screen is positive, antibody identification is performed using a larger panel, and antigen-negative donor units are selected when appropriate. Historical clinically significant antibodies remain important even when they are no longer detectable because an anamnestic response can cause delayed hemolysis.

Crossmatching verifies compatibility of the selected donor red-cell unit with the patient. An electronic crossmatch can be used in appropriately validated systems for eligible patients with a current negative antibody screen and no history of clinically significant antibodies. A serologic antiglobulin crossmatch is required in many patients with current or historical antibodies. The exact rules follow AABB standards, regulatory requirements, and institutional policy.

Sample validity is time limited in patients recently transfused or pregnant because new alloantibodies can emerge. Many transfusion services use a specimen collected within the previous three days for patients transfused or pregnant within the preceding three months, but local policy and applicable standards control. In a massive hemorrhage, emergency-release group O red cells may be issued before typing is complete. Current AABB guidance emphasizes conserving O RhD-negative red cells and switching to type-specific blood promptly once reliable testing permits.

Treatment Strategy & Disposition

The correct transfusion component and urgency are clinical decisions. If bleeding is life threatening, transfusion should not be delayed solely to complete routine compatibility testing. The clinician communicates the emergency, the blood bank documents emergency release, and uncrossmatched red cells are issued according to local policy. Group O RhD-negative red cells are particularly important for patients with childbearing potential when RhD status is unknown, while many protocols use O RhD-positive units for selected adult recipients to preserve limited O-negative inventory.

When an antibody is present, the transfusion service identifies it and provides antigen-negative compatible units. Multiple alloantibodies, autoantibodies, or antibodies to high-prevalence antigens can markedly prolong unit selection. Early communication is crucial before surgery or delivery. Extended phenotype or genotype testing can help match patients who require chronic transfusion, such as those with sickle cell disease, and can reduce future alloimmunization.

A suspected transfusion reaction requires stopping the transfusion, maintaining IV access with compatible fluid, checking patient/unit identity, notifying the transfusion service, and evaluating the reaction according to its phenotype. Repeat ABO testing, DAT, visual hemolysis assessment, and other studies are selected based on the event. The pretransfusion process is one part of a closed-loop safety system that includes correct indication, bedside identification, component monitoring, and reaction recognition.

Epidemiology / Risk Factors

• Red-cell alloantibodies are more common in patients with prior pregnancy or transfusion exposure.
• Chronically transfused populations, especially sickle cell disease, have substantial alloimmunization risk.
• ABO-incompatible transfusion is rare but remains a preventable catastrophic event often linked to identification or process errors.
• O RhD-negative red cells represent a minority of the donor supply and face disproportionate emergency demand.
• Massive hemorrhage protocols are designed to provide rapid component access while routine testing catches up.

Investigations

Special Situations

Pharmacology

Prognosis / Complications

• Compatible transfusion is highly safe when identification and laboratory processes are followed.
• Delayed hemolytic transfusion reactions can occur when a prior antibody reappears after exposure.
• Patients with multiple antibodies may face future delays in finding compatible units.
• Early genotype/phenotype-guided matching can improve transfusion support in selected chronically transfused patients.
• Outcome in emergency-release transfusion depends primarily on hemorrhage control and physiologic resuscitation; delaying blood can be more dangerous than the small compatibility uncertainty.

Patient Education / Counseling

• Encourage patients with known red-cell antibodies to tell every hospital or transfusion service and to carry antibody information when provided.
• Explain that a positive antibody screen does not mean infection; it means an immune antibody may react with donor red cells.
• Patients receiving chronic transfusion should know why extended matching or genotyping may be used.
• Explain emergency-release blood when time does not permit full testing.
• Review symptoms of transfusion reactions, including fever, chills, dyspnea, back pain, dark urine, rash, or hypotension, and instruct patients to report them immediately.

Notes

AABB's 2026 revision on group O red-cell utilization emphasizes moving to type-specific blood as soon as pretransfusion testing permits and using local policies for RhD-positive emergency units in appropriate RhD-negative recipients. This preserves scarce O-negative inventory without compromising urgent care.

Anti-CD38 monoclonal antibodies can create broad reactivity in indirect antiglobulin testing. Baseline type and screen plus phenotype or genotype before therapy simplifies later transfusion support. Laboratories use validated techniques such as DTT-treated reagent cells, with awareness that DTT destroys certain antigens including Kell, so matching strategy must account for that limitation.

The transfusion service should be involved early when a patient has a rare phenotype, multiple alloantibodies, sickle cell disease, planned transplantation, or a history of difficult compatibility. Minutes spent communicating early can prevent hours of delay later.

References

1. AABB Association Bulletin on Use of Group O Red Blood Cells, revised 2026 — Link
2. AABB Standards and Transfusion Medicine Resources — Link